$1,320,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues"
You can find more data on corporate lobbying on Quiver Quantitative.
BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/19, 11/12 and 0 sales.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BMY Insider Trading Activity
BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- DAVID V ELKINS (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,850,016.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BMY Hedge Fund Activity
We have seen 1,131 institutional investors add shares of BMY stock to their portfolio, and 1,103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 65,718,198 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $3,544,839,600
- AQR CAPITAL MANAGEMENT LLC added 16,332,924 shares (+172.6%) to their portfolio in Q4 2025, for an estimated $880,997,920
- CAPITAL INTERNATIONAL INVESTORS removed 11,395,497 shares (-35.2%) from their portfolio in Q4 2025, for an estimated $614,673,108
- JPMORGAN CHASE & CO removed 10,813,011 shares (-12.5%) from their portfolio in Q4 2025, for an estimated $583,253,813
- WELLINGTON MANAGEMENT GROUP LLP removed 10,234,541 shares (-59.7%) from their portfolio in Q4 2025, for an estimated $552,051,141
- MARSHALL WACE, LLP added 9,310,682 shares (+607.1%) to their portfolio in Q4 2025, for an estimated $502,218,187
- PACER ADVISORS, INC. removed 9,304,698 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $501,895,410
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BMY Analyst Ratings
Wall Street analysts have issued reports on $BMY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
- B of A Securities issued a "Buy" rating on 12/15/2025
- Guggenheim issued a "Buy" rating on 12/12/2025
To track analyst ratings and price targets for BMY, check out Quiver Quantitative's $BMY forecast page.
BMY Price Targets
Multiple analysts have issued price targets for $BMY recently. We have seen 15 analysts offer price targets for $BMY in the last 6 months, with a median target of $60.0.
Here are some recent targets:
- Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026
- Seamus Fernandez from Guggenheim set a target price of $72.0 on 04/08/2026
- Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 04/08/2026
- Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
- Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
- David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026
- Emily Field from Barclays set a target price of $75.0 on 02/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
